Regeneron Pharmaceuticals announced Monday that it has agreed to acquire 23andMe’s DNA testing business, including most of its assets, out of bankruptcy. The deal ensures the continuation of popular consumer genetic testing services, with Regeneron vowing to uphold 23andMe’s privacy practices to safeguard customer data.
Source: https://www.washingtonpost.com/business/2025/05/19/23andme-bankruptcy-acquisition-regeneron